Table 1. Clinical and laboratory characteristics of the participants

	Mean±SD	Median	Interquartile range
Age (yr)	8.35±2.61	8.58	5.95, 10.65
Bone age (yr)	7.00±2.57	7.50	5.00, 9.50
Height (cm)	116.57±13.87	119.50	105.50, 128.30
Height SDS	–2.34±0.44	–2.23	–2.46, –2.07
Weight (kg)	23.69±8.19	22.30	17.20, 28.40
Weight SDS	–1.51±0.86	–1.51	–2.14, –1.01
BMI (kg/m2)	16.90±2.50	16.34	15.02, 18.20
BMI SDS	–0.28±1.00	–0.33	–0.82, 0.20
PGH-T (ng/mL)	6.36±2.23	6.73	4.78, 8.38
PGH-L (ng/mL)	5.08±1.00	4.78	3.21, 6.78
PGH-A (ng/mL)	5.02±2.63	5.04	2.61, 7.13
IGF1 (ng/mL)	190.60±81.96	177.60	130.90, 227.00
Insulin (mIU/L)	8.36±3.32	8.65	5.40, 10.12
Glucose (mg/dL)	87.39±5.73	87.00	83.00, 92.00
HOMA-IR	1.82±0.77	1.80	1.17, 2.34
Total cholesterol (mg/dL)	167.43±31.48	168.00	148.00, 185.00
Triglyceride (mg/dL)	86.58±45.73	76.00	54.00, 109.00
HDL-C (mg/dL)	60.20±10.71	60.00	54.00, 66.00
LDL-C (mg/dL)	92.13±20.82	92.00	79.00, 103.00
AST (IU/L)	28.09±5.37	27.50	24.00, 32.00
ALT (IU/L)	13.67±6.34	12.00	10.00, 14.00

Bone age was evaluated using the Greulich-Pyle method.
SDS, SD score; BMI, body mass index; PGH-T, peak growth hormone level determined by two stimulation tests; PGH-L, peak growth hormone level stimulated by L-dopa; PGH-A, peak growth hormone level stimulated by arginine; IGF1, insulin-like growth factor 1; HOMA-IR, homeostatic model assessment-insulin resistance; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.